DOCSLIB.ORG

Summary of Product Characteristics 1. Name Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Summary of Product Characteristics 1. Name Of SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT PRAZEPAM EG 10 mg tablets PRAZEPAM EG 20 mg tablets PRAZEPAM EG 15 mg/ml oral drops, solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Prazepam EG 10 mg tablets: each tablet contains 10 mg prazepam. Excipient with known effect: Lactose: 119,60 mg Prazepam EG 20 mg tablets: each tablet contains 20 mg prazepam. Excipient with known effect: Lactose: 83,80 mg Prazepam EG 15 mg/ml oral drops, solution: each ml contains 15 mg prazepam (equivalent to 30 drops). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablets. Prazepam EG 10 mg tablets: Blue, round, flat tablets, scored on one side. Prazepam EG 20 mg tablets: White, round, flat tablets, scored on one side. The tablet can be divided into equal doses. Oral drops, solution. Prazepam EG 15 mg/ml oral drops, solution: Blue solution characterised by mint and anethole odour and taste. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Symptomatic treatment of anxiety. Benzodiazepines are indicated in the event of severe incapacitating symptoms or if these symptoms lead to an extreme suffering for the patient. 4.2 Posology and method of administration Posology Adults The recommended dose should be of 10-30 mg/day, and higher doses up to 60 mg should be reserved for most severe anxious conditions in psychiatric patients. This dosage can be administered in one or several doses every 24 hours, e.g.: 1/11 a.) a full dose at night or b.) ¼ of the dose in the morning, ¼ at midday and ½ at night or c.) ½ of the dose in the morning and ½ at night. Elderly patients In elderly or debilitated patients, it is advisable to start treatment with a 10 or 15 mg dose of prazepam, distributed over the day, and to subsequently increase it if necessary. Usually the therapeutic response can be obtained with half dose (see section 4.4). Paediatric population Adolescents (12-17 years of age). It is advisable to decrease the dosage depending on the age and weight of the patient and to not exceed 1 mg per kg body weight per day. The recommended dose should be of 10-30 mg/day, and higher doses up to 60 mg should be reserved for most severe anxious conditions in psychiatric patients. There are no clinical data on the use of prazepam in children under 6 years of age (see section 4.3, 4.4). The use of benzodiazepines in children below 6 years of age is only permitted after evaluation and under the surveillance of a specialist (neuropaediatrician, psychiatrist) who will decide on its posology. In many cases the administration of benzodiazepines meets an occasional or temporary need and so will be of short duration. Renal impairment, hepatic impairment A decrease in dose should be considered in patients with impaired renal or mild to moderate impaired hepatic function. Method of administration In some cases the patient’s state of health may necessitate longer-term administration. Each case where benzodiazepines are used over a prolonged period should be regularly re-evaluated by the doctor. Caution is advised when treatment is stopped. A decrease in dose should be considered in patients with impaired renal or mild to moderate impaired hepatic function. Duration of treatment Treatment should be as short as possible. The patient’s state of health should be regularly re- evaluated and the need for continued treatment re-examined, especially if the patient has no symptoms. Total duration of treatment should normally not exceed 8-12 weeks, including the dose withdrawal phase. In some cases, it may be necessary to prolong treatment beyond the maximum recommended period; if this happens, the patient’s state of health should be re-evaluated first by a doctor. Treatment should be initiated at the minimum recommended dose. The maximum dose should not be exceeded. 4.3 Contraindications Patients with a history of hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Patients with a history of hypersensitivity to other benzodiazepines. Cases of myasthenia gravis. 2/11 Children under 6 years of age; use in children below 6 years of age is intended for rare and specific indications after evaluation and under the surveillance of a specialist (neuropaediatrician, psychiatrist) Patients with severe respiratory insufficiency. Sleep apnoea syndrome. Benzodiazepines are contraindicated in patients with severe hepatic insufficiency as it may precipitate encephalopathy. 4.4 Special warnings and precautions for use Prazepam EG is not recommended in psychiatric disorders and psychotic states where anxiety is not one of the major factors. As a result, prazepam should only be used as an adjuvant in psychoses. Elderly patients. Minor drowsiness and/or a decrease in ability to concentrate, as well as a reduction in muscle tone may present in the elderly or in those with weak muscles. In the elderly or very weak, it is advisable to start treatment at a lower dose e.g. 10 or 15 mg dose of prazepam, distributed over the day, and to subsequently increase it if necessary. Paediatric population There are no clinical data on the use of prazepam in children under 6 years of age. Benzodiazepines must not be administered to children without careful evaluation of the need of such treatment. Duration of treatment should be as short as possible. The use of benzodiazepines in children below 6 years of age is intended for rare and specific indications after evaluation and under the surveillance of a specialist (neuropaediatrician, psychiatrist) (see section 4.3. Contraindications). In children 6 to 18 years of age, dose reduction is recommended depending on the patient’s age and body weight. Prazepam EG should only be prescribed to children after thourough evaluation of the indication. There are no clinical data as to the use of Prazepam EG in children below 6 years of age. Children are more sensitive to the effects of benzodiazepines on the CNS, because development of the metabolism scheme is still incomplete so that formation of inactive metabolites might not be possible or not be complete. Renal impairment. A decrease in dose should be considered in patients with impaired renal function. Hepatic impairment. A decrease in dose should be considered in patients with mild to moderate impaired hepatic function. Benzodiazepines are contraindicated in patients suffering from severe hepatic impairment, as they may precipitate encephalopathy. Tolerance. Benzodiazepines can induce symptoms of tolerance. Dependence. Administration of benzodiazepines can lead to the development of physical and psychological dependence. The risk of dependence increases with the dose and duration of treatment. Furthermore, it is greater in patients with a history of alcoholism or drug dependence. Once a person has become physically dependent, sudden withdrawal of treatment is accompanied by symptoms of withdrawal. These might be headache, muscular pains, extreme anxiety, tension, agitation, confusion and irritability. In severe cases, following symptoms may appear: 3/11 derealisation, depersonalisation, hyperacusis, numbness and tingling in the extremities, hypersensitivity to light, noise and physical contact, hallucinations or epileptic fits. Rebound anxiety: when treatment is stopped a temporary syndrome may occur, in which the symptoms that led to benzodiazepines being prescribed reappear in an amplified form. It may be accompanied by other reactions including mood changes, anxiety or sleep disturbances and restlessness. As the risk of withdrawal or rebound symptoms is greater after sudden withdrawal of treatment, a gradual reduction in dose is recommended. Progressive discontinuation of treatment The procedure should be clearly detailed to the patient. Besides the need of progressive dose tapering phase, patients should be informed of the risk of rebound phenomena in order to minimise the anxiety that might follow the symptoms linked with discontinuation, even if progressive. The patient should be informed about the possibly uncomfortable nature of this period. Duration of treatment. Duration of treatment should be as short as possible (see “Posology and Method of Administration”) and should not exceed 8-12 weeks, including the dose withdrawal phase. If the treatment is to be extended beyond this period, the situation should be re-evaluated. For patients with a history of dependence, see the section “Undesirable effects”. Amnesia. Benzodiazepines can cause anterograde amnesia which generally occurs within a few hours after ingestion of the product. As a consequence, in order to minimise this risk, patients need to be sure that they will have 7 to 8 hours of uninterrupted sleep following intake of the medicinal product (see also section “Indesirable effects”). For patients with a history of dependence, see the section “Undesirable effects”. Epilepsy Although epileptic fits may occur following the abrupt withdrawal of treatment, this risk will probably be greater with benzodiazepines that have a short half-life. One should bear this in mind when treating patients who have already suffered from epilepsy. Psychiatric and paradoxical reactions. Reactions like restlessness, agitation, irritability, aggressiveness, delirium, rage, nightmares, delusions, hallucinations, psychoses, inappropriate behaviour and other adverse behavioural effects are known to occur when using benzodiazepines. If these paradoxical reactions occur, Prazepam EG should be discontinued. These reactions are more likely to occur in children and the elderly. Benzodiazepines are not indicated in the primary treatment of psychotic disorders. Benzodiazepines should not be used as monotherapy in the treatment of depression or anxiety associated with depression (as they may trigger suicide in these patients). Alcohol Benzodiazepines should be used with extreme caution in patients with a history of alcoholism or drug dependence. As far as the concomitant intake of alcohol is concerned, see the section “Interaction with other medicinal products and other forms of interaction”. 4/11 Risk from concomitant use of opioids Concomitant use of Prazepam EG and opioids may result in sedation, respiratory depression, coma and death.
Load more

Recommended publications
  • The Misuse of Benzodiazepines Among High-Risk Opioid Users in Europe
    EMBARGO — 7 JUNE 7. 6. 2018 UPDATED 11:30 Central European Time/CET (10:30 Western European Time/WET/Lisbon) Proof - 28 May 2018 not for circulation PERSPECTIVES ON DRUGS The misuse of benzodiazepines among high-risk opioid users in Europe Benzodiazepines are a widely prescribed I Introduction group of medicines with a range of clinical uses that include treating Benzodiazepines have a range of clinical uses and are among the most commonly prescribed medicines globally. anxiety, insomnia and managing alcohol They are useful in the short-term treatment of anxiety and withdrawal. This group of medicines is insomnia, and in managing alcohol withdrawal (Medicines often misused by high-risk opioid users, and Healthcare Products Regulatory Agency, 2015). Like all medicines, benzodiazepines can produce side effects. They and this is associated with considerable may also be misused, which we define as use without a morbidity and mortality. This paper prescription from a medical practitioner or, if prescribed, when describes the impact of benzodiazepines they are used outside accepted medical practice or guidelines. misuse on the health and treatment of While the misuse of benzodiazepines has been identified high-risk opioid users. as a concern for large groups in the general population, for example, among elderly people and women, this analysis focuses specifically on misuse among high-risk opioid users (1), a group of people among whom these medicines have been linked with severe treatment challenges and implicated in considerable numbers of drug-related deaths. It is important to stress that much benzodiazepine prescribing to high-risk drug users is done with legitimate therapeutic aims in mind.
    [Show full text]
  • Drugs of Abuse: Benzodiazepines
    Drugs of Abuse: Benzodiazepines What are Benzodiazepines? Benzodiazepines are central nervous system depressants that produce sedation, induce sleep, relieve anxiety and muscle spasms, and prevent seizures. What is their origin? Benzodiazepines are only legally available through prescription. Many abusers maintain their drug supply by getting prescriptions from several doctors, forging prescriptions, or buying them illicitly. Alprazolam and diazepam are the two most frequently encountered benzodiazepines on the illicit market. Benzodiazepines are What are common street names? depressants legally available Common street names include Benzos and Downers. through prescription. Abuse is associated with What do they look like? adolescents and young The most common benzodiazepines are the prescription drugs ® ® ® ® ® adults who take the drug Valium , Xanax , Halcion , Ativan , and Klonopin . Tolerance can orally or crush it up and develop, although at variable rates and to different degrees. short it to get high. Shorter-acting benzodiazepines used to manage insomnia include estazolam (ProSom®), flurazepam (Dalmane®), temazepam (Restoril®), Benzodiazepines slow down and triazolam (Halcion®). Midazolam (Versed®), a short-acting the central nervous system. benzodiazepine, is utilized for sedation, anxiety, and amnesia in critical Overdose effects include care settings and prior to anesthesia. It is available in the United States shallow respiration, clammy as an injectable preparation and as a syrup (primarily for pediatric skin, dilated pupils, weak patients). and rapid pulse, coma, and possible death. Benzodiazepines with a longer duration of action are utilized to treat insomnia in patients with daytime anxiety. These benzodiazepines include alprazolam (Xanax®), chlordiazepoxide (Librium®), clorazepate (Tranxene®), diazepam (Valium®), halazepam (Paxipam®), lorzepam (Ativan®), oxazepam (Serax®), prazepam (Centrax®), and quazepam (Doral®).
    [Show full text]
  • The Emergence of New Psychoactive Substance (NPS) Benzodiazepines
    Issue: Ir Med J; Vol 112; No. 7; P970 The Emergence of New Psychoactive Substance (NPS) Benzodiazepines. A Survey of their Prevalence in Opioid Substitution Patients using LC-MS S. Mc Namara, S. Stokes, J. Nolan HSE National Drug Treatment Centre Abstract Benzodiazepines have a wide range of clinical uses being among the most commonly prescribed medicines globally. The EU Early Warning System on new psychoactive substances (NPS) has over recent years detected new illicit benzodiazepines in Europe’s drug market1. Additional reference standards were obtained and a multi-residue LC- MS method was developed to test for 31 benzodiazepines or metabolites in urine including some new benzodiazepines which have been classified as New Psychoactive Substances (NPS) which comprise a range of substances, including synthetic cannabinoids, opioids, cathinones and benzodiazepines not covered by international drug controls. 200 urine samples from patients attending the HSE National Drug Treatment Centre (NDTC) who are monitored on a regular basis for drug and alcohol use and which tested positive for benzodiazepine class drugs by immunoassay screening were subjected to confirmatory analysis to determine what Benzodiazepine drugs were present and to see if etizolam or other new benzodiazepines are being used in the addiction population currently. Benzodiazepine prescription and use is common in the addiction population. Of significance we found evidence of consumption of an illicit new psychoactive benzodiazepine, Etizolam. Introduction Benzodiazepines are useful in the short-term treatment of anxiety and insomnia, and in managing alcohol withdrawal. 1 According to the EMCDDA report on the misuse of benzodiazepines among high-risk opioid users in Europe1, benzodiazepines, especially when injected, can prolong the intensity and duration of opioid effects.
    [Show full text]
  • A Review of the Evidence of Use and Harms of Novel Benzodiazepines
    ACMD Advisory Council on the Misuse of Drugs Novel Benzodiazepines A review of the evidence of use and harms of Novel Benzodiazepines April 2020 1 Contents 1. Introduction ................................................................................................................................. 4 2. Legal control of benzodiazepines .......................................................................................... 4 3. Benzodiazepine chemistry and pharmacology .................................................................. 6 4. Benzodiazepine misuse............................................................................................................ 7 Benzodiazepine use with opioids ................................................................................................... 9 Social harms of benzodiazepine use .......................................................................................... 10 Suicide ............................................................................................................................................. 11 5. Prevalence and harm summaries of Novel Benzodiazepines ...................................... 11 1. Flualprazolam ......................................................................................................................... 11 2. Norfludiazepam ....................................................................................................................... 13 3. Flunitrazolam ..........................................................................................................................
    [Show full text]
  • Analysis of Benzodiazepines in Blood by LC/MS/MS Application Note
    Analysis of Benzodiazepines in Blood by LC/MS/MS Application Note Forensic Toxicology Authors Introduction Hazel Rivera and G. Stewart Walker The analysis of benzodiazepines is of great interest Flinders University to forensic toxicologists. Adelaide, South Australia Australia Screening of these compounds has been problem- atic since immunoassays are often not sufficiently Peter Stockham and D. Noel Sims specific or sensitive enough for low-dosage benzo- Forensic Science South Australia diazepines, especially in blood. Benzodiazepines Adelaide, South Australia have been analyzed using gas chromatography/ Australia nitrogen phosphorus detector (GC/NPD) [1], gas John M. Hughes chromatography/electron capture detector (GC/ECD) [1], and gas chromatography/mass spec- Agilent Technologies, Inc. trometry (GC/MS) [2, 3]. Many benzodiazepines are Pleasanton, CA polar and thermally labile, making them diffi-cult, USA if not impossible, to analyze with GC or GC/MS without derivatization. Some of the com- Abstract pounds cannot be derivatized for improved chromatographic behavior. A sensitive and selective method for the simultaneous screening and identification of 13 benzodiazepines and Screening for benzodiazepines can also be carried 5 metabolites in human blood using the Agilent LC/MSD out using HPLC with UV detection [4], but this Trap is described. The method uses liquid-liquid extrac- technique lacks both the sensitivity and specificity tion followed by reverse-phase LC/MS/MS (liquid required for forensic applications. Furthermore, chromatography/tandem mass spectrometry). The some of the newer benzodiazepines, like fluni- technique is suitable for screening analysis and trazepam, have much lower usage dose ranges and high-confidence identification of the analytes at their faster clearance, and therefore require identifica- lowest reported dosage concentrations using only 500 µL tion at lower levels.
    [Show full text]
  • Drug, Drug Metabolites Trade Names, Street Name
    Drug, Drug metabolites Trade names, street name Opioids Methadone Dolophine, Methadose EDDP Buprenorphine Buprenex, Suboxone, Subutex Norbuprenorphine cis-Tramadol Ultram O-DSM-Tramadol Codeine Tylenol3, Tylenol4, Tylenol5, morphine metabolite Morphine Astromorph, Avinza, DepoDur, Duramorph, Kadian, MS Contin; heroin metabolite Fentanyl Actiq, Duragesic, Fentora, Lonsys, Sublimaze Hydrocodone Synalgos_DC, Anexsia, Damason-P, Hycodan, Lortab, Maxidone, Norco, Panacet, Vicodin, Zydone; codeine metabolite Hydromorphone Dilaudid; Hymorphan; morphine and hydrocodone metabolite Meperidine Demerol, Mepergan Naloxone Narcan, Nalone, Evzio, Narcanti Naltrexone Revia, Depade, Vivitrol Oxycodone Oxycontin (with acetaminophen: Endocet, Percocet, Roxicet; with aspirin: Endodan, Percodan, Roxiprin; with ibuprofen: Combunox) Oxymorphone Numorphan, Opana; oxycodone metabolite Stimulants Amphetamine Benzedrine, Dexedrine, Adderall, Vyvanse, speed; could be methamphetamine metabolite; if so, typically < 30 percent of parent Methamphetamine Desoxyn, methedrine, Vicks inhaler (D- and L-isomers are not resolved; low concentrations expected if the source is Vicks); selegeline (Atapryl, Carbex, Carbex, Eldepryl, Zelapar) metabolite MDMA XTC, ecstacy, Adam, bean, , Mercedes, Molly, New Yorkers, peace, roll, white dove, X MDA MDMA and MDEA metabolite 6-MAM Heroin metabolite Benzoylecgonine Cocaine metabolite, Esterom Cocaine Crack; parent drug rarely observed due to short half-life. Phencyclidine PCP, angel dust MDEA Eve Benzodiazepines Alprazolam Xanax alpha-Hydroxyalprazolam
    [Show full text]
  • INFORMATION for the USER PRAZEPAM EG 15 Mg/Ml Oral
    PACKAGE LEAFLET: INFORMATION FOR THE USER PRAZEPAM EG 15 mg/ml oral drops, solution prazepam Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Prazepam EG is and what it is used for 2. What you need to know before you take Prazepam EG 3. How to take Prazepam EG 4. Possible side effects 5. How to store Prazepam EG 6. Contents of the pack and other information 1. What Prazepam EG is and what it is used for The active substance of Prazepam EG is prazepam. Prazepam is a benzodiazepine derivative and is indicated to treat symptoms of anxiety. Benzodiazepines are used to treat severe incapacitating symptoms or symptoms leading to an extreme suffering for the patient. Prazepam EG is used to treat anxiety and nervous tension requiring sedative treatment. 2. What you need to know before you take Prazepam EG DO NOT take Prazepam EG: if you are allergic to prazepam or any of the other ingredients of this medicine (listed in section 6) if you have experienced an allergic reaction to other benzodiazepines in the past if you suffer from
    [Show full text]
  • Benzodiazepine Equivalence Table
    benzo.org.uk : Benzodiazepine Equivalence Table http://www.benzo.org.uk/bzequiv.htm « back exit frame back to frame www.benzo.org.uk » BENZODIAZEPINE EQUIVALENCE TABLE (Benzodiazepine Equivalency Table) Revised April 2007 This Benzodiazepine Equivalence Table is based on the extensive research and clinical experience of Professor C Heather Ashton , DM, FRCP, Emeritus Professor of Clinical Psychopharmacology at the University of Newcastle upon Tyne, England. Sources: NRHA Drug Newsletter , April 1985 and Benzodiazepines: How they Work & How to Withdraw (The Ashton Manual ), 2002. The approximate equivalent doses to 10mg diazepam (Valium) are given. For a discussion of half-lives and equivalencies see also the Benzo FAQ document . 2 Approximately Half-life (hrs) Market Benzodiazepines 1 [active Equivalent Aim4 metabolite] Oral dosages (mg) 3 Alprazolam 6-12 0.5 a (Xanax, Xanor, Tafil) Bromazepam 10-20 5-6 a (Lexotan, Lexomil) Chlordiazepoxide 5-30 [36-200] 25 a (Librium) Clobazam 12-60 20 a,e (Frisium) 5 Clonazepam 18-50 0.5 a,e (Klonopin, Rivotril) 5 Clorazepate [36-200] 15 a (Tranxene) Diazepam 20-100 [36-200] 10 a (Valium) Estazolam 10-24 1-2 h (ProSom, Nuctalon) Flunitrazepam 18-26 [36-200] 1 h (Rohypnol) Flurazepam [40-250] 15-30 h (Dalmane) Halazepam [30-100] 20 a (Paxipam) 1 sur 3 01/02/2010 18:46 benzo.org.uk : Benzodiazepine Equivalence Table http://www.benzo.org.uk/bzequiv.htm Ketazolam 30-100 [36-200] 15-30 a (Anxon) Loprazolam 6-12 1-2 h (Dormonoct) Lorazepam 10-20 1 a (Ativan, Temesta, Tavor) Lormetazepam 10-12 1-2 h (Noctamid) Medazepam 36-200 10 a (Nobrium) Nitrazepam 15-38 10 h (Mogadon) Nordazepam 36-200 10 a (Nordaz, Calmday) Oxazepam (Serax, Serenid, 4-15 20 a Serepax, Seresta) Prazepam [36-200] 10-20 a (Centrax, Lysanxia) Quazepam (Doral) 25-100 20 h Temazepam (Restoril, Normison, 8-22 20 h Euhypnos) Triazolam 2 0.5 h (Halcion) Non-benzodiazepines with similar effects 1, 6 Zaleplon 2 20 h (Sonata) Zolpidem (Ambien, Stilnoct, 2 20 h Stilnox) Zopiclone 5-6 15 h (Zimovane, Imovane) Eszopiclone 6 3 h (Lunesta) (9 in elderly) 1.
    [Show full text]
  • Forensic Intoxication with Clobazam: HPLC/DAD/MSD Analysis Paula Proenc¸Aa,*, Helena Teixeiraa,B, Joa˜O Pinheiroa, Estela P
    Forensic Science International 143 (2004) 205–209 Forensic intoxication with clobazam: HPLC/DAD/MSD analysis Paula Proenc¸aa,*, Helena Teixeiraa,b, Joa˜o Pinheiroa, Estela P. Marquesa,b, Duarte Nuno Vieiraa,b aNational Institute of Legal Medicine—Delegation of Coimbra, Largo da Se´ Nova, 3000-213 Coimbra, Portugal bFaculty of Medicine, University of Coimbra, Largo da Se´ Nova, 3000-213 Coimbra, Portugal Received 20 November 2003; accepted 1 March 2004 Available online 28 May 2004 Abstract Clobazam (Castillium1, Urbanil1), a benzodiazepine often used as an anxiolytic and in the treatment of epilepsy, is considered a relatively safe drug. The authors present a fatal case with a 49-year-old female, found dead at home. She had been undergoing psychiatric treatment and was a chronic alcoholic. The autopsy findings were unremarkable, except for multivisceral congestion, steatosis and a small piece of a plastic blister pack in the stomach. Bronchopneumonia, bronchitis and bronchiolitis were also diagnosed. Anhigh-performance liquid chromatography (HPLC)/diode array detector (DAD)/mass spectrometry detection (MSD) with electrospray method was developed in order to detect, confirm and quantify clobazam in the post-mortem samples. In the chromatographic separation, a reversed-phase column C18 (2:1 Â 150 mm, 3.5 mm) was used with a mobile phase of methanol and water, at a 0.25 ml/min flow rate. Carbonate buffer (pH 10.5) and 20 ml of prazepam (100 mg/ml) as internal standard were added to the samples. A simple and reliable liquid–liquid extraction method for the determination of clobazam in post-mortem samples was described.
    [Show full text]
  • Commonly Prescribed Psychotropic Medications
    Commonly Prescribed Psychotropic Medications Antipsychotics (used in the treatment of Anti-depressants Anti-obsessive Agents schizophrenia and mania) Typical Antipsychotics Tricyclics Haldol (haloperidol) *Anafranil (clomipramine) Anafranil (clomipramine) Loxitane (loxapine) Asendin (amoxapine) Luvox (fluvoxamine) Mellaril (thioridazine) Elavil (amitriptyline) Paxil (paroxetine) Moban (molindone) Norpramin (desipramine) Prozac (fluoxetine) Navane (thiothixene) Pamelor (nortriptyline) Zoloft (sertraline) Prolixin (fluphenazine) Sinequan (doxepin) Serentil (mesoridazine) Surmontil (trimipramine) Antianxiety Agents Stelazine (trifluoperazine) Tofranil (imipramine) Ativan (lorazepam) Thorazine (chlorpromazine) Vivactil (protiptyline) BuSpar (buspirone) Trilafon (perphenazine) Centrax (prazepam) SSRIs *Inderal (propranolol) Atypical Antipsychotics Celexa (citalopram) *Klonopin (clonazepam) Abilify (aripiprazole) Lexapro (escitalopram) Lexapro (escitalopram) Clozaril (clozapine) *Luvox (fluvoxamine) Librium (chlordiazepoxide) Risperdal (risperidone) Paxil (paroxetine) Serax (oxazepam) Seroquel (quetiapine) Prozac (fluoxetine) *Tenormin (atenolol) Zyprexa (olanzapine) Zoloft (sertraline) Tranxene (clorazepate) Valium (diazepam) MAOIs Xanax (alprazolam) Mood Stabilizers *Antidepressants, especially Nardil (phenelzine) (used in the treatment SSRIs, are also used in the Parnate (tranylcypromine) of bipolar disorder) treatment of anxiety. Depakene (valproic acid) Depakote Others Stimulants Eskalith Desyrel (trazadone) (used in the Page 1 of 4 Lithobid
    [Show full text]
  • Safe Drug Use for the Recovering Addict Or Alcoholic
    Safe Drug Use for the Recovering Addict or Alcoholic 3995 South Cobb Drive Smyrna, Georgia 30080 770-434-4567 1-800-329-9775 www.ridgeviewinstitute.com Revised September 2012 Safe Drug Use for the Recovering Addict or Alcoholic People in recovery must be especially careful when taking any Pain meds kind of over-the-counter (otc) or prescription medications. • Pain meds are tricky for people in recovery. Most otc pain Many otc meds contain alcohol or other ingredients that relievers are fine — ibuprofen (Advil, Motrin), naproxyn could endanger their sobriety by triggering a relapse. Even (Aleve), Tylenol. These meds are very effective for many physicians not familiar with addiction may prescribe meds aches and pains. There are times when the addict/alcoholic that are not safe for the addict/alcoholic. People in recovery must have stronger pain meds, such as narcotics, after must be vigilant in protecting their sobriety. They must read surgery or for a severe injury. If the narcotics are necessary ingredients, ask questions, and use much caution in using any and taken only as directed, this is not considered a relapse. kind of medication. If in doubt about a specific medication, It is normal for this to cause anxiety in recovering people, contact your psychiatrist/addictionologist or another knowl- so it is recommended that the recovering person prepare edgeable person for guidance. themselves before surgery when possible with extra recovery support and pre-planning regarding pain relief. In Important points: any case, the recovering person should not handle the pain • Never take a medication given to you by someone else meds themselves.
    [Show full text]
  • Poisonings and Deaths Caused by Benzodiazepine Drugs in Costa Rica, from 2007 to 2014
    MOJ Toxicology Research Article Open Access Poisonings and deaths caused by benzodiazepine drugs in costa rica, from 2007 to 2014 Abstract Volume 4 Issue 1 - 2018 Background information: Medications are the main cause of poisoning in Costa Rica, and benzodiazepines are reported in many of the poisonings that occurred. María del Mar Castillo Guerrero, Freddy Arias Mora Objective: Analyze the poisonings and deaths caused by benzodiazepines in Costa Rica. Department of Pharmacology, University of Costa Rica, Costa Rica Method: A retrospective study was conducted. It included all the cases of poisonings and deaths by benzodiazepine poisonings in Costa Rica from 2007 to 2014. A logistic regression Correspondence: María del Mar Castillo Guerrero, Faculty of analysis was conducted to determine the probability of a person of dying by benzodiazepine Pharmacy, University of Costa Rica, San Pedro, Montes de Oca, poisoning. A descriptive analysis was performed with the information of the total population San José, Costa Rica, Tel 50625118317, Fax 50625118350, of people intoxicated by benzodiazepines. Email [email protected] Results: People intoxicated by benzodiazepines have higher possibilities of dying, Received: February 08, 2018 | Published: February 19, 2018 than those who were not poisoned by benzodiazepines. Most cases of poisoning with benzodiazepines correspond to women in the 30 to 44 age range. Attempting suicide is the main cause of poisoning. The combination of benzodiazepines with other substances such as antidepressants, anticonvulsants and alcohol prevails in cases of deaths by poisoning with benzodiazepines. Discussion and Conclusion: The main cause of poisoning is suicide attempt, so the potential high suicide risk that exists with the use of these drugs should be monitored.
    [Show full text]